Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
100% citation coverage2 peer-reviewed sources
Moderna says its combined flu-COVID vaccine mRNA-1083 met Phase 3 primary endpoints with higher immune responses in adults 50 and older. The readout matters for BD teams and investors tracking combo-vaccine competition, FDA posture, and next filing milestones.
Intelligence Snapshot
Executive Summary
Moderna's mRNA-1083 elicited higher immune responses against influenza and SARS-CoV-2 compared to licensed vaccines in adults aged 50 and older , meeting Phase 3 primary endpoints in NCT06694389 and NCT06097273.
Key Insights
-
The FDA rejected Moderna's application for filing because the company did not follow 2024…
The FDA rejected Moderna's application for filing because the company did not follow 2024 guidance to test the product against a CDC-recommended flu vaccine , creating regulatory uncertainty around filing strategy and approval timing.
-
Competitive combo-vaccine programs remain active: Novavax's experimental…
Competitive combo-vaccine programs remain active: Novavax's experimental COVID-19-influenza combination vaccine generated a strong immune response in adults aged 65 and older in late-stage testing.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Loading intelligence…
Quick Answer
Moderna's mRNA-1083 elicited higher immune responses against influenza and SARS-CoV-2 compared to licensed vaccines in adults aged 50 and older , meeting Phase 3 primary endpoints in NCT06694389 and NCT06097273.
Key Questions
- Why is FDA refusing to review Moderna flu vaccine?
- How effective is the Moderna mRNA flu shot?
- Which Novavax COVID-flu combo vaccine shows strong immune response in trial?
- What should investors and BD teams watch next?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for mRNA-1083.
Unlock full calendar →Moderna pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Contents11 sections
Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
Moderna says its combined flu-COVID vaccine mRNA-1083 met Phase 3 primary endpoints with higher immune responses in adults 50 and older. The readout matters for BD teams and investors tracking combo-vaccine competition, FDA posture, and next filing milestones.
IntelligenceRegulatory Impact
FDA, HHS, and CDC decisions frame this story. Regulatory relevance is high for COVID-19, with mRNA-1083 most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- Moderna's mRNA-1083 elicited higher immune responses against influenza and SARS-CoV-2 compared to licensed vaccines in adults aged 50 and older, meeting Phase 3 primary endpoints in NCT06694389 and NCT06097273.
- The FDA rejected Moderna's application for filing because the company did not follow 2024 guidance to test the product against a CDC-recommended flu vaccine, creating regulatory uncertainty around filing strategy and approval timing.
- Competitive combo-vaccine programs remain active: Novavax's experimental COVID-19-influenza combination vaccine generated a strong immune response in adults aged 65 and older in late-stage testing.
IntelligenceCompetitive Intelligence
Moderna, GSK, and Novavax are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.
Phase 3 immunogenicity readout for mRNA-1083
Moderna's combined flu-COVID vaccine mRNA-1083 met its primary endpoints by eliciting higher immune responses against both influenza and SARS-CoV-2 compared to licensed flu and COVID-19 vaccines in adults aged 50 and older. The company completed two Phase 3 studies: NCT06694389 and NCT06097273.
The vaccine demonstrated an acceptable safety and reactogenicity profile in adults aged 50 years and older.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for COVID-19. Expect implications for pricing, access, and launch sequencing.
FDA regulatory stance and filing pathway uncertainty
The Phase 3 readout arrives amid regulatory friction. The FDA rejected Moderna's application for filing because the company did not follow 2024 guidance to test the product against a CDC-recommended flu vaccine. This decision raises questions about whether Moderna's existing clinical data will satisfy FDA requirements for a new filing or whether additional head-to-head trials will be needed.
For BD teams and investors, the regulatory posture is a critical watch item. The FDA's rejection underscores the agency's position on flu-vaccine comparator selection, which affects the approval pathway for mRNA-1083.
IntelligenceStrategic Takeaways
Moderna's mRNA-1083 elicited higher immune responses against influenza and SARS-CoV-2 compared to licensed vaccines in adults aged 50 and older , meeting Phase 3 primary endpoints in NCT06694389 and NCT06097273. The FDA rejected Moderna's application for filing because the company did not follow 2024 guidance to test the product against a CDC-recommended flu vaccine , creating regulatory uncertainty around filing str
Competitive landscape for flu-COVID combination vaccines
Moderna is not alone in pursuing a single-shot flu-COVID vaccine. Novavax's experimental COVID-19-influenza combination vaccine generated a strong immune response in adults aged 65 and older in late-stage testing.
The competitive field also includes licensed comparators. Moderna's mRNA flu vaccine was 26.6% more effective than the standard dose flu shot from GSK in a clinical study.
IntelligenceEvidence Quality
Grounded in 2 peer-reviewed sources.
Clinical trial portfolio and development history
Moderna's mRNA-1083 program has progressed through multiple phases. Earlier Phase 1 and Phase 2 studies (NCT05827926) assessed mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults and have been completed. The company also ran a Phase 2 study (NCT06864143) investigating immunogenicity, reactogenicity, and safety in adults aged 18 to under 65 years, as well as a Phase 2 safety and immunogenicity study (NCT06508320) examining product attributes.
What happens next for mRNA-1083
The immediate catalyst is regulatory engagement. The company's next steps likely include formal FDA meetings to clarify the path forward and determine whether the existing Phase 3 data can support a filing or whether additional comparative studies are needed.
For investors and BD teams, the timeline remains unclear. The Phase 3 immunogenicity readout is clinically positive but does not automatically translate to an approval date or commercial launch window without regulatory clarity. Watch for announcements around FDA feedback, any additional trial initiation, or partnership discussions that might accelerate or reshape the development strategy.
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT05827926 | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | COMPLETED | PHASE1, PHASE2 | ModernaTX, Inc. |
| NCT06694389 | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age | COMPLETED | PHASE3 | ModernaTX, Inc. |
| NCT06864143 | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age | COMPLETED | PHASE2 | ModernaTX, Inc. |
| NCT06508320 | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) | COMPLETED | PHASE2 | ModernaTX, Inc. |
| NCT06097273 | A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age | COMPLETED | PHASE3 | ModernaTX, Inc. |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| Pfizer | COVID-19 | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | COVID-19 | 2 |
| Merck Sharp & Dohme LLC | COVID-19 | 1 |
| National Institute of Environmental Health Sciences (NIEHS) | COVID-19 | 1 |
| York University | COVID-19 | 1 |
| Mayo Clinic | COVID-19 | 1 |
Frequently Asked Questions
Why is FDA refusing to review Moderna flu vaccine?
The FDA rejected Moderna's application for filing because the company did not follow 2024 guidance to test the product against a CDC-recommended flu vaccine. Moderna did not include the required comparator vaccine in its clinical trial design.
How effective is the Moderna mRNA flu shot?
Moderna's mRNA flu vaccine was 26.6% more effective than the standard dose flu shot from GSK in a clinical study. For the combined flu-COVID vaccine mRNA-1083, the vaccine elicited higher immune responses against both influenza and SARS-CoV-2 compared to licensed vaccines in adults aged 50 and older.
Which Novavax COVID-flu combo vaccine shows strong immune response in trial?
Novavax's experimental COVID-19-influenza combination vaccine generated a strong immune response in adults aged 65 and older in late-stage testing, positioning it as a competitor to Moderna's mRNA-1083 in the combination-vaccine space.
What should investors and BD teams watch next?
Monitor FDA feedback to Moderna on the 2024 guidance requirement and any announcements around supplementary trials or filing strategy. Track whether Moderna initiates additional clinical work or pursues regulatory meetings that could clarify the approval pathway. Watch for competitive updates from Novavax and any partnership announcements that might alter development timelines or commercial strategy.
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About COVID-19
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow mRNA-1083 developments
FDA covid-19 alerts and mRNA-1083 pipeline updates, every Monday.
- Sources analyzed
- 2
- Evidence strength
- 90/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- Barriers and Facilitators to Use of Digital Health Tools by Healthcare Practitioners — This study identifies key barriers and facilitators impacting healthcare practitioners' use of digit…